Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA)’s share price was up 4.6% on Wednesday . The stock traded as high as $3.24 and last traded at $3.20, with a volume of 55,453 shares trading hands. The stock had previously closed at $3.06.

DRNA has been the subject of several analyst reports. Chardan Capital reiterated a “neutral” rating on shares of Dicerna Pharmaceuticals in a research note on Thursday, April 14th. Stifel Nicolaus decreased their price objective on shares of Dicerna Pharmaceuticals from $20.00 to $16.00 and set a “buy” rating for the company in a research note on Tuesday, May 10th. Jefferies Group reiterated a “buy” rating and issued a $19.00 price objective on shares of Dicerna Pharmaceuticals in a research note on Tuesday, May 10th. Leerink Swann reiterated a “buy” rating on shares of Dicerna Pharmaceuticals in a research note on Tuesday, May 10th. Finally, Cowen and Company reiterated a “buy” rating on shares of Dicerna Pharmaceuticals in a research note on Tuesday, May 10th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Dicerna Pharmaceuticals has a consensus rating of “Buy” and an average price target of $11.95.

The company’s market capitalization is $66.74 million. The stock has a 50 day moving average of $3.26 and a 200 day moving average of $4.60.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last announced its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.86) by $0.10. Equities research analysts expect that Dicerna Pharmaceuticals Inc. will post ($3.34) earnings per share for the current year.

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.